Reopening the Critical Window: How Psilocybin May Unlock Neuroplasticity for Healing
By Tommaso Barba, Neuroscientist
Psychedelic-assisted therapy has captured growing public and scientific interest for its promising outcomes in mental health. Unlike conventional treatments that require daily medication, substances like psilocybin (the active compound in “magic mushrooms”) can lead to lasting positive changes after just one or two guided sessions.
Many participants report beneficial effects from depressive and anxious patterns for months following a single psychedelic experience. What makes this possible?
Emerging neuroscience suggests that psychedelics such as psilocybin might temporarily reopen a “critical window” of neuroplasticity in the brain, a period when the brain is especially malleable and able to form new connections. This reopening of neuroplasticity may help explain how psilocybin can change the brain, allowing entrenched emotional and cognitive patterns to shift more rapidly than conventional treatments.
What Is the ‘’Critical Window of Brain Plasticity’’ in Psilocybin Therapy?
In early childhood, our brains go through critical periods, special developmental windows of time when we can easily absorb new skills like language, emotional regulation or social cues. Past a certain age, these windows close, and learning those skills becomes much harder.
Recent research suggests that psychedelics such as psilocybin can reopen similar critical windows in the adult brain[1][2]. In essence, psilocybin and related psychedelics temporarily return the brain to a more youthful, adaptable state.
A groundbreaking 2023 study by the team of neuroscientist Gül Dölen demonstrated this phenomenon in mice. After a single dose of psilocybin, the animals’ brains entered an enhanced learning state for about two weeks[2]. During that time, the mice were much more receptive to social conditioning, a task that usually only young mice can learn easily.
Intriguingly, different psychedelics appear to reopen the brain’s critical window for different lengths of time:
Ketamine (a shorter-acting psychedelic-like drug) left the window open for around ~2 days,
LSD extended plasticity for around 3 weeks
Ibogaine for about 4 weeks[2]
Psilocybin roughly 2 weeks
Scientists suspect this might not be a coincidence[3].
How Psilocybin Increases Neuroplasticity in the Brain
At the cellular level, psychedelics such as psilocybin promote a surge in neural connectivity and growth. Research shows that psychedelics stimulate the brain to sprout new dendritic spines and rewire neural pathways, essentially “softening” rigid networks and possibly making the brain more “flexible”.
Psychologically, this manifests as a period of openness, cognitive flexibility, and heightened sensitivity to one’s environment and emotions[4]. People often become more able to view their life with new perspectives, break out of old thought loops, and embrace positive changes during this time. Importantly, this open state is both “fertile and vulnerable”[5].
In a supportive setting, it’s fertile ground for therapeutic breakthroughs. But in a chaotic or negative environment, a person might be more sensitive to stress or adverse experiences. In other words, the brain is especially impressionable during the post-psilocybin period, which is why set and setting (mindset and environment) both before, during and after a psychedelic experience are absolutely critical.
Why Timing Matters in Psilocybin Therapy: Harnessing the Neuroplasticity Window for Healing
The recognition of this critical plasticity window has shifted how experts approach psychedelic therapy. The days and weeks following a psilocybin therapy session are seen as a unique opportunity for change and growth.
During this window, the brain’s heightened malleability means that beneficial behaviours, thought patterns, and emotional insights can take root more deeply than usual[6]. Therapeutic activities undertaken in this period often have an outsized impact.
For example, engaging in talk therapy or journaling a few days after a psilocybin session can lead to profound realisations, because the mind is primed to make new connections and find new meaning in life events.
One clinical psychologist described this post-psychadelic session period as an “unfolding process”, patients may continue to discover insights and shifts in perspective for days or weeks after the psilocybin's acute effects have worn off. In essence, the therapeutic process doesn’t end when the session ends, it’s just beginning.
Why Integration is Essential After A Psilocybin Session
Many psychedelic therapists emphasise the importance of integration: the process of reflecting on and solidifying the lessons from the psychedelic experience. Integration might include journaling about one’s journey, counselling sessions, meditation, artwork, or even intentional time in nature.
These practices help translate the often abstract or intense insights from the psilocybin session into real-life changes. Research supports that this integration phase is crucial.
As one neuroscientist put it, “The open state of the critical period may be an opportunity for a post-treatment integration period to maintain the learning state.”[7]
In practical terms, clinicians using psilocybin advise patients to treat the next days and weeks as a gentle extension of the therapy: avoid overly stressful or toxic environments, seek supportive people and activities, and deliberately practice new ways of thinking or being. By doing so, patients essentially “teach” their malleable brains new and healthier patterns while the window is open.
Can Psilocybin Increase Vulnerability During the Neuroplasticity Window?
It’s worth noting that this period of elevated plasticity following a psilocybin therapy session can amplify any influence , positive or negative. Just as a nurturing environment can greatly reinforce healing, a negative influence such as a traumatic event or lack of support during this window could potentially set someone back.
This is the “vulnerable” side of the fertile window[5]. It underscores why psychedelic therapy is typically done in controlled, therapeutic settings and followed by professional support. The goal is to ensure that the impressions made on the open mind are beneficial, guiding the individual toward improvement rather than harm.
Is One Psilocybin Session Enough for Lasting Change?
Given that psilocybin’s effects unfold over a window of weeks, a natural question is whether multiple sessions lead to better outcomes than a single session. Early research in psychedelic therapy for depression often involved two dosing sessions: an initial guided psilocybin experience, followed by a second session several weeks later. The idea was that the second psilocybin dose might “recharge” or extend the plasticity window, allowing patients to deepen their progress.
But is more always better? The emerging answer: it depends.
What Research Says About Two Psilocybin Therapy Sessions
Some studies have indeed found that two psilocybin sessions can yield stronger or more sustained relief from symptoms. For instance, one meta-analysis in 2022 noted that patients who received a second psilocybin session (usually within a month of the first) showed greater improvements in depression scores that lasted up to six months[8]. In that analysis, depression symptoms dropped rapidly after the first psilocybin session (often peaking around one week after the dose) and remained significantly improved for months.
A second dose appeared to reinforce these gains, potentially by reopening the plasticity window and allowing further therapeutic work during another period of high neural flexibility. This aligns with anecdotal reports: some individuals find the first psilocybin session “opened the door” and a follow-up session helped them step through it more fully, especially if they had more emotional material to process.
What Research Shows About Single-Dose Psilocybin Therapy
However, newer research has brought a more nuanced perspective. A comprehensive 2024 review compared outcomes of one vs. two psilocybin sessions across multiple depression trials. It concluded that both single-dose and two-dose treatments led to significant reductions in depression, and overall there was no clear statistical advantage to having that second dose in terms of final outcomes[9].
In other words, many people did just as well with one properly supported psilocybin session as others did with two. The researchers noted that when two-dose programs showed a benefit, it was not certain this was solely due to getting an extra dose, other factors could be at play[9]. For example, patients who had two sessions also had more therapeutic contact time, preparation, and integration, which in itself can improve results.
Why Therapeutic Support May Matter More Than Dose Frequency
The takeaway is that quality may matter more than quantity. The therapeutic context, skilled facilitation, trust and rapport, integration support, is likely as important as the number of dosing sessions[10]. If a single psilocybin journey is supported by a strong therapeutic container, it can catalyze tremendous change.
On the other hand, a poorly supported psychedelic experience might not yield lasting benefit even if repeated. As one analysis put it, psilocybin’s effects work in concert with “common psychotherapeutic factors” and a supportive environment[5]. Simply taking another dose is not a guarantee of progress unless the person is ready to make use of the new window it opens.
When Is a Second Psilocybin Dose Useful?
Clinicians suggest it can be helpful in certain cases. For someone with very entrenched depression or trauma, the first psilocybin session may only scratch the surface of what needs healing. A second session, typically spaced a few weeks later, can reopen the window of plasticity and allow the person to delve deeper once they’ve had time to integrate the first experience.
It’s also considered if the first session was beneficial but incomplete, for example, if some psychological insights emerged but important emotions remain unresolved, or if the individual feels there is “more work to do.” In these instances, a second carefully-prepared psilocybin journey might reinforce and expand the gains from the first[11].
What’s crucial is that the individual approaches it intentionally: Are they actively integrating lessons from the first session? Are they entering the second session with clear intentions (not simply chasing a bigger “high”)? Ideally, the decision to do a follow-up dose is made with therapeutic guidance, focusing on whether the person has maximized the benefits of the first experience and genuinely needs another round to progress further.
How Psilocybin Therapy May Transform Mental Health Treatment
The discovery of a psychedelic-induced critical window of plasticity points toward a new paradigm in treating mental health conditions. Rather than viewing psilocybin as a typical drug that directly “cures” depression or anxiety, we can see it as a catalyst, it opens a temporary door through which therapeutic change can enter.
This model places much more emphasis on the patient’s active participation and the therapist’s guidance, and less on taking a pill every day. In a way, the patient becomes a co-creator of their healing during the plasticity window, rather than a passive recipient of a drug effect.
Is Psilocybin Therapy Safe? Risks and Clinical Considerations
It’s important to temper excitement with caution. While results so far are promising, psychedelic therapy is still under investigation in clinical trials, and it’s not a panacea. Not everyone will have a life-changing experience or even respond to the treatment. Some people may need additional support, or different approaches. There are also risks in psilocybin therapy: without proper screening and guidance, a psychedelic session can be overwhelming or even destabilising for vulnerable individuals.
Set and setting, screening, and integration are paramount – psychedelic therapy is most effective and safe when done with trained professionals in controlled settings. As the “window of plasticity” concept implies, the brain is wide open to influence during this time. That influence must be skillfully directed. In unsupervised or recreational contexts, there’s no guarantee of positive influences, which is why experts urge caution and discourage people from experimenting on their own, especially if dealing with serious mental health issues[6].
Psilocybin, Neuroplasticity, and the Future of Psychedelic-Assisted Therapy
The idea of a critical window of plasticity induced by psilocybin offers a hopeful explanation for the profound transformations observed in psychedelic therapy. By temporarily unlocking the brain’s innate capacity to rewire and heal, psilocybin allows people to do hard therapeutic work in a matter of weeks – work that might otherwise take years, or might not happen at all under a hardened, depressed brain state.
This window, however, does not work magic on its own. It requires us to rise to the occasion: to engage with the therapy process, to surround ourselves with support and positive influences, and to put forth effort in translating insights into lasting change. In that sense, psychedelic therapy is a partnership between the chemical and the personal.
Psilocybin opens the door, and it’s up to the individual (with the help of therapists or guides) to walk through it and embrace the possibilities on the other side.
As research continues, we will better understand how long these windows induced by psychedelics stay open in humans, how factors like dose size or frequency influence them, and how to best support people during this crucial time.
For now, the stories emerging – of people overcoming years of depression, finding peace from trauma, or breaking free from addiction – underscore the potential of this approach. Psychedelic-assisted therapy, centered around carefully harnessing the critical window of plasticity, could very well transform the future of mental health care.
It teaches us that healing is not just about the substances we take, but when and how we nurture the brain’s ability to change. With respect, caution, and scientific diligence, we stand at the dawn of a new chapter – one where deep, lasting mental health improvements might be achieved in weeks, not years, by tapping into the brain’s remarkable capacity to rewire itself[8][9].
Frequently Asked Questions About Psilocybin and Neuroplasticity
Does psilocybin increase neuroplasticity?
Emerging research suggests that psilocybin may temporarily increase neuroplasticity, the brain’s ability to reorganise and form new neural connections. Studies indicate that psychedelics can stimulate the growth of dendritic spines and enhance neural connectivity, creating a window during which the brain becomes more adaptable to new experiences, insights, and behaviours.
How long does neuroplasticity last after psilocybin?
Research suggests that the heightened neuroplastic state following psilocybin may last for several days to a few weeks. Animal studies have shown that psychedelics can reopen a “critical window” of plasticity during which learning and emotional change may occur more easily. The exact duration in humans is still being investigated, but this window is believed to be an important period for therapeutic integration.
Can psilocybin permanently change the brain?
Psilocybin does not permanently alter the brain in a fixed structural sense. However, the temporary increase in neuroplasticity may allow individuals to form new neural pathways and patterns of thinking. When combined with supportive therapeutic environments and integration practices, these changes can lead to lasting psychological and behavioural shifts.
Is psilocybin therapy safe?
Psilocybin therapy is currently being studied in clinical trials for conditions such as depression, trauma, and addiction. When conducted in carefully controlled settings with screening, preparation, and integration support, research suggests it can be safe for many participants. However, psychedelics are powerful substances and may be unsuitable for certain individuals, particularly those with specific psychiatric vulnerabilities. Professional guidance and responsible therapeutic contexts are therefore essential.
About the Author
Tommaso Barba
Tommaso Barba is a PhD research scientist at the Centre for Psychedelic Research at Imperial College London. His research explores the effects of psychedelic compounds on the brain, well-being, and human flourishing, with particular interest in short-acting psychedelics such as 5-MeO-DMT.
His work also investigates the potential role of psychedelic substances in relationships, intimacy, and sexual well-being. Tommaso authored the first research study examining the long-term effects of psychedelic use on sexual functioning.
He is currently involved in the world’s first naturalistic research study exploring the impact of psilocybin combined with psychological support on relationship wellbeing in collaboration with Beautiful Space.
References:
[1] [2] [3] [7] Study Shows Psychedelic Drugs Reopen ‘Critical Periods’ for Social Learning | Johns Hopkins Medicine
[4] [5] [6] Catalyst for change: Psilocybin’s antidepressant mechanisms—A systematic review - PMC
https://pmc.ncbi.nlm.nih.gov/articles/PMC12099018/
[8] Trajectory of Antidepressant Effects after Single- or Two-Dose Administration of Psilocybin: A Systematic Review and Multivariate Meta-Analysis
https://www.mdpi.com/2077-0383/11/4/938
[9] Comparison between Single-Dose and Two-Dose Psilocybin Administration in the Treatment of Major Depression: A Systematic Review and Meta-Analysis of Current Clinical Trials - PMC
https://pmc.ncbi.nlm.nih.gov/articles/PMC11352277/
[10] [11] One vs. Two Psilocybin Doses: Unravelling the Evidence
https://www.odysseypbc.com/blog-posts/one-vs-two-psilocybin-doses-evidence
[12] [13] [14] [15] Are two doses of psilocybin better than one_new.docx
file://file_00000000a5fc71f5af08c340537afe2f